Peer Review History

Original SubmissionJune 2, 2021
Decision Letter - Salvatore V Pizzo, Editor

PONE-D-21-18235Functional analysis of N-acetylglucosaminyltransferase-I knockdown in 2D and 3D neuroblastoma cell culturesPLOS ONE

Dear Dr. Schwalbe,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please note the extensive comments from Reviewer No. 1.  If these issues can be addressed, it is likely that this manuscript will be accepted for publication.

Please submit your revised manuscript by Nov 02 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Salvatore V Pizzo

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf.

2. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

3. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels. In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

4. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

********** 

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

********** 

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

********** 

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

********** 

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: In the manuscript by Hall et al., together with their previous paper (ref. 18-20) the authors generated Mgat1 (encodes GnT-I) knock out neuroblastoma cells by CRIPR/Cas9 and obtained mutant cells with aberrant N-glycosylation. The mutant cells showed altered cell morphology and growth properties compared to wild-type parental cells. The authors also showed that the expression of several proteins including MMP, receptor-tyrosine kinase and cytoskeletal proteins were significantly changed in mutant cells.

The experiment seems to be well designed and conducted, and the results ae convincing to support their conclusion. The manuscript is well constructed and written in precise English.

Even though the manuscript largely lacks the mechanistic insights how N-glycans regulate and what proteins is most responsible for these cellular phenotypes, the phenomena itself might be informative to the reader of glycobiology and tumor biology.

I think the publication of the manuscript can be considered if the following concerns are addressed.

Major point

1. through the manuscript

GnT-1 and GnT-2 should be GnT-I and GnT-II (Roman, not Arabian)

2. The schematic drawing to show N-glycans structures and how GnT-I and GnT-II work on the structures should be briefly presented on Figure 1A for beginner readers.

3. Figure 1D

The samples should be run on the same gel and blotted on the same membrane for each blot.

4. Figure 9A

The image is very poor and the samples should be run on the same gel and blotted on the same membrane for each blot.

5. The authors should more discuss the relevance of their finding to the human clinical situations. For instances, human neuroblastoma is classified into stage 1 to 4 and 4S. Do you have any information about the expression of GnT-I with different stages?

Minor point

Lime 108

paladin>paladin

Line 132

two dimensional (2D) versus three dimensional (3D) > 2D and 3D

the abbreviations were already defined and not needed here

Figure 1C

“NB_1 (Mgat1)” should be “NB_1 (-Mgat1)”

Figure 2A

the scale bar should be included into the image

Figure 2B

What is OG? Outgrowth? “Neurite Length” and “Neurite Width” are better.

Figure 2D

Need the scale bar.

Figure 3B

Need the scale bar.

Figure 3C Y-axis

What is the unit?

Figure 3D

Need the scale bar.

Figure 5A and 5B

Need the scale bar

Figure 5C, Y-axis

Should be “Cell invasion index (ratio to spheroid size)”

Figure 5D, Y-axis

Need the unit pixels?

Figure 6

See the comment on Figure 5.

Figure 7B and 7D, Y-axis

Should be “Gelatinase activity (Mutant/NB_1)

Figure 8A

The cell line names are missing.

Figure 9C and 9D, Y-axis

Should be “Band intensity (Mutant/NB_1)” or “Relative expression (Mutant/NB_1)”.

********** 

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Kazuma Sakamoto

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Point-by-point comments to reviewer

5. Review Comments to the Author

We wish to thank the reviewer for a thorough review as the comments have improved the manuscript.

Authors’ answers to the questions above.

The answers to questions made by reviewer were positive. However, we have addressed availability of group data supporting the mean. Groups data has been uploaded as supplementary group data excel file. Also, we have attached a file: S1_Raw_images which has unmodified images of western blot, lectin blots, gelatinase gels and coomassie blue stained SDS gels.

Reviewer #1: In the manuscript by Hall et al., together with their previous paper (ref. 18-20) the authors generated Mgat1 (encodes GnT-I) knock out neuroblastoma cells by CRIPR/Cas9 and obtained mutant cells with aberrant N-glycosylation. The mutant cells showed altered cell morphology and growth properties compared to wild-type parental cells. The authors also showed that the expression of several proteins including MMP, receptor-tyrosine kinase and cytoskeletal proteins were significantly changed in mutant cells.

The experiment seems to be well designed and conducted, and the results ae convincing to support their conclusion. The manuscript is well constructed and written in precise English.

Even though the manuscript largely lacks the mechanistic insights how N-glycans regulate and what proteins is most responsible for these cellular phenotypes, the phenomena itself might be informative to the reader of glycobiology and tumor biology.

I think the publication of the manuscript can be considered if the following concerns are addressed.

Major point

1. through the manuscript

GnT-1 and GnT-2 should be GnT-I and GnT-II (Roman, not Arabian)

Authors response: This has been changed throughout the manuscript.

2. The schematic drawing to show N-glycans structures and how GnT-I and GnT-II work on the structures should be briefly presented on Figure 1A for beginner readers.

Authors response: A schematic drawing has been added as Figure 1A. The figure legend was updated, lines 300-303. The figure is stated in the text of the results, lines 292-294.

3. Figure 1D

The samples should be run on the same gel and blotted on the same membrane for each blot.

Figure 1D was changed to Figure 1E due to insertion of the schematic drawing requested by reviewer. The samples were run on the same blot as shown and can also be viewed in the S1_Raw_images file. We have removed lines on blots for clarification.

4. Figure 9A

The image is very poor and the samples should be run on the same gel and blotted on the same membrane for each blot.

The samples were run on the same blot as shown and can also be viewed in the S1_Raw_images file. For clarification purposes, we have removed lines on blots. In some cases, the 2D and 3D samples were separated by standards as shown in figure. The standard was included on blot to illustrate the samples were on the same blot.

5. The authors should more discuss the relevance of their finding to the human clinical situations. For instances, human neuroblastoma is classified into stage 1 to 4 and 4S. Do you have any information about the expression of GnT-I with different stages?

Currently, information is lacking about the expression of GnT- I with the various stages of NB. However, we have elaborated on GnT-I in favorable and unfavorable NB in the 2nd paragraph of the discussion.

“… Again, reinforcing the relative great cell invasiveness of NB_1(-Mgat1) cells. Based on our 3D cell invasion studies, NB cells expressing complex N-glycans were less invasive than those expressing exclusively oligomannose. As such, our current results support a past clinical NB study which showed that GnT-V, the enzyme which initiates β1,6-branchpoints, was of higher abundance in favorable stages (1, 2 and 4s) than unfavorable stages (3 and 4) of NB [26]. Thus, it would be of great interest to evaluate whether unfavorable NB patients have lowered expression of GnT-I in tumor tissues compared to those with favorable NB. Further the cell culturing technique appears to have a major impact on interpreting cell invasiveness of NB cells.”

Minor point

Lime 108

paladin>paladin

This has been corrected.

Line 132

two dimensional (2D) versus three dimensional (3D) > 2D and 3D

the abbreviations were already defined and not needed here

This has been corrected.

Figure 1C

“NB_1 (Mgat1)” should be “NB_1 (-Mgat1)”

This has been corrected.

Figure 2A

the scale bar should be included into the image

A scale bar (in µm) has been added.

Figure 2B

What is OG? Outgrowth? “Neurite Length” and “Neurite Width” are better.

Outgrowth has been changed to neurite. Also pixels have been converted to µm.

Figure 2D

Need the scale bar.

A scale bar (in µm) has been added.

Figure 3B

Need the scale bar.

A scale bar (in µm) has been added.

Figure 3C Y-axis

What is the unit?

µm2

Figure 3D

Need the scale bar.

A scale bar (in µm) has been added.

Figure 5A and 5B

Need the scale bar

A scale bar (in µm) has been added.

Figure 5C, Y-axis

Should be “Cell invasion index (ratio to spheroid size)”

Authors reply: The y-axis represents invasion area/sphere area.

Since there appeared to be some confusion, we changed the figure panels. Figure 5B shows how the invasion was calculated (invasion=invasive area – sphere area). The y-axis of figure 5C was changed to invasion area/sphere area. A reference for the analysis has been added in the methods (Berens EB, Holy JM, Riegel AT, Wellstein A. A Cancer Cell Spheroid Assay to Assess Invasion in a 3D Setting. Journal of visualized experiments : JoVE. 2015;(105). Epub 2015/12/10. doi: 10.3791/53409. PubMed PMID: 26649463; PubMed Central PMCID: PMCPMC4692745) (see line 244). Panel D represent plots of sphere area versus invasion area for each cell line to determine Pearson’s correlation coefficients between these two variables. The linear fits show a positive and significant correlation of the two variables, and the rationale for representing cell invasiveness of the different cell lines using the invasion/sphere versus cell line plot. The figure legend and results section has been changed accordingly.

Figure 5D, Y-axis

Need the unit pixels?

This panel has been removed and sphere area versus invasion area plot has been added. The units are in µm.

Figure 6

See the comment on Figure 5.

Scale bar has been added. The y-axis of Panels D,E,F have been changed as described above for figure 5. Panels with bar graphs of sphere area versus cell line have been removed.

Figure 7B and 7D, Y-axis

Should be “Gelatinase activity (Mutant/NB_1)

The label of Y-axis has been changed.

Figure 8A

The cell line names are missing.

The names of cell lines have been added.

Figure 9C and 9D, Y-axis

Should be “Band intensity (Mutant/NB_1)” or “Relative expression (Mutant/NB_1)”.

The y-axis was changed to Band intensity (Mutant/NB_1).

Attachments
Attachment
Submitted filename: Point by point response to reveiwers.pdf
Decision Letter - Salvatore V Pizzo, Editor

Functional analysis of N-acetylglucosaminyltransferase-I knockdown in 2D and 3D neuroblastoma cell cultures

PONE-D-21-18235R1

Dear Dr. Schwalbe,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Salvatore V Pizzo

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors well addressed my concerns.

I do not have additional requirements and recommend the publication of the manuscript in PLOS One.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Kazuma Sakamoto

Formally Accepted
Acceptance Letter - Salvatore V Pizzo, Editor

PONE-D-21-18235R1

Functional analysis of N-acetylglucosaminyltransferase-I knockdown in 2D and 3D neuroblastoma cell cultures

Dear Dr. Schwalbe:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Salvatore V Pizzo

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .